Literature DB >> 10808192

New pituitary oncogenes.

A P Heaney1, S Melmed.   

Abstract

Pituitary tumors are common monoclonal neoplasms which cause considerable morbidity and mortality. Several molecular events underlying pituitary tumorigenesis have been elucidated in recent years, but no tumor marker has clearly emerged which assists clinical and therapeutic decisions. Activating mutations and loss of inactivating mutations, together with hypothalamic hormones, circulating hormones, growth factors and cytokines cooperatively ensure the inexorable expansion of the initial mutated pituitary cell clone. This review describes new developments in our understanding of the molecular mechanisms involved in the pathogenesis of pituitary tumors. The availability of molecular probes will allow the early prediction of tumor behavior, identify targets for designing subcellular pituitary tumor therapy and provide novel approaches to pituitary tumor management.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10808192     DOI: 10.1677/erc.0.0070003

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  13 in total

1.  Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors.

Authors:  Matilde Lombardero; Sergio Vidal; Robert Hurta; Alba Román; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Inhibitory effects of anti-sense PTTG on malignant phenotype of human ovarian carcinoma cell line SK-OV-3.

Authors:  Gang Chen; Jing Li; Fujun Li; Xiao Li; Jianfeng Zhou; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.

Authors:  Anderson Alves da Rocha; Ricardo Rodrigues Giorgi; Sandra Valeria de Sa; Maria Lucia Correa-Giannella; Maria Angela Fortes; Ana Mercedes Cavaleiro; Marcio Carlos Machado; Valter Angelo Cescato; Marcello Delano Bronstein; Daniel Giannella-Neto
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

4.  Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.

Authors:  K H Ruebel; L Jin; S Zhang; B W Scheithauer; R V Lloyd
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

Review 5.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

Review 6.  Role of transcription factors in the pathogenesis of pituitary adenomas: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

Review 7.  Pituitary tumors: prognostic indicators.

Authors:  Wolfgang Saeger
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

8.  The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.

Authors:  Seda Turgut; Muzaffer Ilhan; Saime Turan; Ozcan Karaman; Ilhan Yaylim; Ozlem Kucukhuseyin; Ertugrul Tasan
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

9.  Immunolocalization of Pit-1 in gonadotroph nuclei is indicative of the transdifferentiation of gonadotroph to lactotroph cells in prolactinomas induced by estrogen.

Authors:  Jorge Humberto Mukdsi; Ana Lucía De Paul; Sonia Muñoz; Agustín Aoki; Alicia Inés Torres
Journal:  Histochem Cell Biol       Date:  2004-06-09       Impact factor: 4.304

10.  No evidence for WT1 involvement in a beta-catenin-independent activation of the Wnt signaling pathway in pituitary adenomas.

Authors:  J Schittenhelm; T Psaras; J Honegger; K Trautmann; R Meyermann; R Beschorner
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.